Resmetirom is under clinical development by Madrigal Pharmaceuticals and currently in Pre-Registration for Non-Alcoholic Steatohepatitis (NASH). According to GlobalData, Pre-Registration drugs for Non-Alcoholic Steatohepatitis (NASH) does not have sufficient historical data to build an indication benchmark PTSR for Pre-Registration. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Resmetirom LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Resmetirom (MGL-3196, VIA-3196, THR-Beta agonist 3196) is under development for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis. The therapeutic candidate is formulated as tablet and orally administered. The therapeutic candidate acts by targeting beta-selective thyroid hormone receptor.
It was also under development for the treatment of heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH).
For a complete picture of Resmetirom’s drug-specific PTSR and LoA scores, buy the report here.